Table 2.
Phenotypic changes that occur upon overexpression or inhibition of PTPL1 expression : organization by tissues and cell lines.
Tissue | Cell lines | Phenotypic Observations | PTPL1 effect |
---|---|---|---|
Hematopoietic cells | Jurkat cells | PTPL1 overexpression inhibits Fas apoptosis [8] | ↓apoptosis |
U937 myelomono-cytic leukemia cell | SLV inhibitory peptide restores Fas apoptosis [63] | ↓apoptosis | |
Colon | DLD-1 | SLV inhibitory peptide restores Fas apoptosis [54] | ↓apoptosis |
SW480 | PTPL1 overexpression increases Fas apoptosis [61] | ↑apoptosis | |
Inhibition of PTPL1 expression increases apoptosis induced by Oxaliplatin [64] | ↓apoptosis | ||
HCT-116 | Inhibition of PTPL1 expression increases Fas apoptosis [65] | ↓apoptosis | |
Inhibition of PTPL1 expression prevents RIL-induced Src inactivation [36] | ↓ Src activation | ||
Primary cultured cancer cells | SLV inhibitory peptide restores Fas apoptosis [62] | ↓Apoptosis | |
Stomach | TMK1 | PTPL1 overexpression decreases Fas apoptosis [57] | ↓apoptosis |
Pancreas | Capan-1 pancreatic cancer cells | PTPL1 overexpression decreases Fas apoptosis [58] | ↓apoptosis |
Panc89 pancreatic cancer cells | Vanadate induces Fas sensitivity. SLV inhibitory peptide restores Fas apoptosis [58] |
↓apoptosis | |
INS-1 β-cells pancreatic β-cells | PTPL1 overexpression inhibits INS-1 cell growth and antagonizes Wnt3a proliferative action[86] | ↓ cell growth | |
Melanocytes | FEMX OM431 LU1205 |
Expression of PTPL1 reduces cell surface Fas level. Inhibition of PTPL1 expression or expression of dominant-negative up-regulate surface Fas levels [59][66] |
↓apoptosis |
Breast | MCF7 | Inhibition of PTPL1 expression fails to restore Fas apoptosis and inhibits antioestrogen-induced apoptosis [73] PTPL1 overexpression dephosphoryles IRS-1 and inhibits IGF-1 survival signaling [74] Inhibition of PTPL1 expression induces xenograft growth, cell growth on Matrigel, cell invasiveness and Src activation [85] |
↑apoptosis ↓ cell growth ↓ cell invasiveness |
T47D | Inhibition of PTPL1 expression induces cell growth on Matrigel, cell invasiveness and Src activation [85] | ↓ cell growth | |
Brain | D566 Glioblastoma |
Inhibition of PTPL1 expression increases Fas apoptosis [60] | ↓apoptosis |
Ovary | SKOV3 | Inhibition of PTPL1 expression promotes invasiveness and Her2 signaling [76] | ↓ cell invasiveness |
Lung | TIG3 embryonic fibroblasts | Inhibition of PTPL1 expression or expression of dominant- negative up-regulates surface Fas levels [59] | ↓apoptosis |
A549 | PTPL1 expression is necessary for inhibition by necl2 of Her2 signaling, cell movement and survival [77] | ↑apoptosis | |
Squamous cell carcinomas of the head and neck | PCI-15A Fas resistant | Inhibition of PTPL1 expression increases Fas apoptosis [67] | ↓apoptosis |
early-passage human tonsil epithelial cells | Inhibition of PTPL1 expression induces anchorage-independent growth with H-Ras and invasive growth of xenografts. PTPL1 expression reverses anchorage-independent growth in cells lacking PTPL1 [81] Overexpression of Her2 with shPTPL1 transfection induced Erk1/2 phosphorylation. PTPL1 overexpression inhibited Erk1/2 and Mek1/2 activation induced by H-Ras, Her2 or EGF-Receptor transfection [80] |
↓ cell growth ↓ cell invasiveness | |
Ewing’s Sarcoma Family of Tumors | TC71 | Reduction of PTPL1 protein levels, using an antisense strategy, leads to reductions in both anchorage-dependent and anchorage-independent cell growth induced by EWS-FLI1[68] | ↑cell growth |
Kidney | HEK293 embryonic cells |
Expression of PTPL1 Inhibits LPA induced cell motility [43] | ↓ cell invasiveness |